The Injectafer lawsuit is a group of product liability cases alleging that the intravenous iron drug Injectafer (ferric carboxymaltose) causes severe hypophosphatemia — dangerously low blood phosphorus — and that its manufacturers knew about the risk for years without adequately warning doctors or patients. The cases were consolidated in federal court in Pennsylvania, three planned bellwether trials were vacated in 2023, and the litigation is now in a confidential settlement phase. No verdicts have been rendered, no settlement figures have been made public, and most law firms have stopped accepting new cases.
What Plaintiffs Are Claiming
The core allegation is failure to warn. Injectafer was approved by the FDA in 2013 for iron deficiency anemia in adults who cannot tolerate or do not respond to oral iron. Plaintiffs say the manufacturers had data before U.S. approval showing the drug strips phosphorus from the body at rates far higher than competing IV iron products, and that they characterized those drops as “asymptomatic” or “transient” to protect sales.
The label history is central to the case. Injectafer’s U.S. label did not include a specific warning about symptomatic hypophosphatemia until February 2020, when the FDA approved an update adding it to the “Warnings and Precautions” section. An earlier change in January 2018 removed language calling the condition “infrequent or mild.” Plaintiffs argue that even the 2020 update is inadequate because it suggests monitoring only after repeat treatments, while medical experts recommend testing before and after every infusion. In addition to failure to warn, plaintiffs bring defective design claims and state-law product liability claims.
Regulators outside the U.S. reached similar conclusions. A November 2020 review by the UK’s Medicines and Healthcare products Regulatory Agency found that ferric carboxymaltose (sold as Ferinject in Europe) is associated with symptomatic hypophosphatemia that can lead to osteomalacia and fractures. The review identified 36 spontaneous reports of patients who developed both conditions; 53 percent of those patients suffered fractures of the hip, pelvis, or femoral neck. European product information was strengthened as a result. Plaintiffs cite these findings as evidence the manufacturers understood the danger globally.
The comparative safety data is a second pillar of the claim. In the FIRM trial, which compared Injectafer to ferumoxytol in nearly 2,000 patients, 50.8 percent of Injectafer patients developed severe hypophosphatemia, versus 0.9 percent of ferumoxytol patients. The PHOSPHARE trials found hypophosphatemia in roughly 74 percent of Injectafer patients compared to about 8 percent of those receiving ferric derisomaltose. A systematic literature review concluded that hypophosphatemia “does not appear to be a class effect for high-dose parenteral iron” but is “a risk specifically related to the use of ferric carboxymaltose.”
The Injuries at the Center of the Cases
Acute symptoms of low phosphorus include severe fatigue, muscle weakness, and pain, which can be mistaken for the anemia Injectafer is meant to treat and lead to missed or delayed diagnoses. With repeated doses, patients in the litigation report developing osteomalacia (softening of the bones), stress fractures in the ribs, spine, pelvis, and hips, respiratory failure, kidney failure, cardiac arrhythmias, seizures, and rhabdomyolysis. Some have required hospitalization and IV phosphate replacement. Phosphorus levels can remain low for months, and some patients have not returned to normal even after two years.
Who Is Being Sued
The primary U.S. defendant is American Regent, Inc., formerly Luitpold Pharmaceuticals, which is listed as the manufacturer on the Injectafer label. Luitpold merged into American Regent at the end of 2018. American Regent is wholly owned by Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., which took over marketing responsibilities for Injectafer in 2017.
Swiss company Vifor Pharma and several of its subsidiaries are also named. Vifor developed the ferric carboxymaltose formula and licensed it to Luitpold for U.S. manufacture and sale, receiving a share of U.S. sales. Vifor’s U.S. subsidiary Relypsa, Inc. manages the American iron business and provides support on manufacturing, marketing, and safety reporting. Plaintiffs allege Vifor participated in clinical trials, marketing decisions, and adverse event reporting and shares responsibility for the failure to warn.
Where the Litigation Stands
The first Injectafer lawsuit was filed in November 2018. Federal cases were consolidated into a mini multidistrict litigation in the U.S. District Court for the Eastern District of Pennsylvania before Judge Wendy J. Beetlestone, with additional cases filed in Philadelphia County state court. The litigation was never certified as a class action; each plaintiff’s claim proceeds individually. In August 2021, Judge Beetlestone denied a motion to consolidate cases for trial.
The defendants argued that FDA approval of Injectafer’s label and design preempted state product liability claims. A Pennsylvania judge rejected that argument and allowed the cases to proceed on defective design and failure to warn theories.
Three bellwether trials were scheduled for 2023 to test the claims before a jury. None went forward. In April 2023, Judge Beetlestone vacated the first trial’s schedule, stayed the litigation, and ordered status updates every 30 days, indicating settlement negotiations. In October 2023, she signed an order establishing a Qualified Settlement Fund between Luitpold Pharmaceuticals and 13 plaintiffs. The first bellwether case, Crockett, was dismissed with prejudice in December 2023, and the second, Atkinson, reached a stipulation of dismissal the same month.
No settlement amounts have been disclosed and no jury has issued a verdict in any Injectafer case. One unofficial estimate has suggested payouts of $200,000 to $500,000 for patients with serious or permanent health consequences, but that figure is speculative and not based on disclosed data. Settlement values reportedly depend on the severity of the injury, the duration of complications, and total medical expenses.
Can You Still File a Claim
By mid-2026, attorneys described the litigation as being in a “mature phase,” and most law firms have stopped accepting new Injectafer cases. Anyone who believes they were injured should speak with a product liability attorney directly about whether a claim is still possible given state statutes of limitations and the current posture of the cases.